HOMA-IR Longevity-Medicine Target Ranges: What Your Number Actually Means

What Is HOMA-IR and How Is It Calculated?

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a simple arithmetic index that estimates whole-body insulin resistance from a single fasting blood draw. The formula, described by Matthews and colleagues in their 1985 Diabetologia paper, requires only two values: fasting serum insulin and fasting plasma glucose. The result correlates well (r = 0.88) with the gold-standard hyperinsulinemic-euglycemic clamp in non-diabetic adults. [1]

The Standard Formula

The widely used clinical formula is:

HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mmol/L]) ÷ 22.5

If your lab reports glucose in mg/dL, convert first: mg/dL ÷ 18.0 = mmol/L. A fasting insulin of 6 µIU/mL with a glucose of 5.0 mmol/L (90 mg/dL) produces a HOMA-IR of 1.33. That same insulin at a glucose of 5.6 mmol/L (101 mg/dL) pushes the score to 1.49.

Why the Formula Matters for Interpretation

Small errors in fasting insulin assay calibration produce large swings in HOMA-IR because insulin appears in the numerator linearly. Fasting insulin varies by assay platform by as much as 20 to 30%, which is why a result should always be interpreted alongside the specific reference range for the assay your lab used. [2] The 2013 HOMA2 calculator, maintained by the Oxford Centre for Diabetes, corrects for hepatic glucose output and non-linear beta-cell secretion, and is considered more accurate when insulin exceeds 20 µIU/mL. [3]

Standard Clinical Reference Ranges for HOMA-IR

Most clinical laboratories flag HOMA-IR above 2.0 or 2.5 as indicating insulin resistance, but these thresholds were derived from population medians rather than from outcomes data. That distinction shapes how longevity clinicians interpret the same number differently from a general practitioner treating a patient who simply wants to avoid a diabetes diagnosis.

Population-Based Cutoffs

A 2013 cross-sectional analysis of 1,168 non-diabetic adults in the NHANES dataset found a median HOMA-IR of 1.6 (interquartile range 1.1 to 2.5) for adults aged 20 to 44 without metabolic syndrome. [4] Using the 75th percentile, the practical threshold for "elevated" in that dataset is approximately 2.5.

The ADA's 2024 Standards of Medical Care in Diabetes do not formally endorse a specific HOMA-IR cutoff for diagnosing prediabetes, preferring HbA1c ≥5.7%, fasting glucose ≥100 mg/dL, or a 2-hour OGTT glucose ≥140 mg/dL. [5] HOMA-IR is, however, recognized as a validated surrogate for insulin resistance in research and risk stratification.

Ethnic and Age Variability

HOMA-IR norms differ meaningfully by population. A study of 2,790 healthy adults in China published in PLOS ONE found the 95th-percentile cutoff was 2.69 in men and 2.22 in women. [6] South Asian adults tend to develop metabolic disease at lower BMI thresholds, and some clinicians apply a more conservative HOMA-IR cutoff of 1.7 in that group. Age also matters: HOMA-IR rises about 0.05 units per decade even in metabolically healthy adults due to the natural decline in insulin sensitivity after age 40. [7]

Longevity-Medicine Target: Why <1.0 Is the New Goal

The conventional cutoff of <2.5 tells you that you are not yet insulin-resistant by population norms. It does not tell you whether your metabolic machinery is running at the level associated with the longest, healthiest lifespan. That distinction is where longevity medicine parts ways with standard clinical care.

The Mortality Signal Below 2.5

The Tehran Lipid and Glucose Study followed 6,894 adults free of diabetes and cardiovascular disease for a median of 12.6 years. Participants in the highest HOMA-IR quartile (median 3.8) had a 2.1-fold higher all-cause mortality risk compared to the lowest quartile (median 0.9) after adjusting for age, sex, smoking, and lipids. [8] Critically, the mortality gradient was continuous, meaning risk was lower at 1.5 than at 2.0, and lower at 1.0 than at 1.5. There was no threshold below which further reduction conferred no additional benefit.

HOMA-IR and Cardiovascular Risk

A 2022 meta-analysis published in Cardiovascular Diabetology pooled 16 prospective cohorts (N = 122,474) and found that each 1-unit rise in HOMA-IR was associated with a 17% higher incident MACE risk (HR 1.17, 95% CI 1.11 to 1.23, P<0.001). [9] The association persisted after exclusion of individuals with baseline diabetes. Participants with a HOMA-IR below 1.0 had the lowest event rates across all age strata.

The <1.0 Target in Practice

The HealthRX longevity-lab framework stratifies HOMA-IR into four action tiers:

| HOMA-IR Range | Interpretation | Recommended Action | |---|---|---| | <1.0 | Longevity-optimal | Maintain; retest annually | | 1.0 to 1.9 | Metabolically adequate; room for improvement | Dietary audit, resistance training 2x/week | | 2.0 to 2.9 | Early insulin resistance | Structured carbohydrate restriction, retest in 90 days | | ≥3.0 | Established insulin resistance | Clinician review; consider metformin, GLP-1, or dedicated metabolic program |

To reach a HOMA-IR below 1.0 at a fasting glucose of 90 mg/dL (5.0 mmol/L), fasting insulin must be below approximately 4.5 µIU/mL. That level is achievable but requires genuine metabolic health, not simply the absence of diabetes.

HOMA-IR, Fasting Insulin, and the Problem With "Normal" Lab Ranges

Fasting insulin is the more sensitive half of the HOMA-IR equation. Many commercial labs flag insulin as normal up to 24 or even 29 µIU/mL. A fasting insulin of 20 µIU/mL with a normal fasting glucose of 90 mg/dL produces a HOMA-IR of 4.4, deep in insulin-resistance territory, yet the lab report may show no out-of-range flags. [10]

What Drives Fasting Insulin Up

Excess dietary refined carbohydrate and fructose, visceral adiposity, sleep deprivation, and chronic psychological stress each raise fasting insulin independent of fasting glucose. An analysis of the CARDIA cohort (N = 5,115, follow-up 25 years) found that adults who averaged fewer than 6 hours of sleep per night had a 47% higher HOMA-IR at year 25 compared to those sleeping 7 to 8 hours, after adjustment for diet and physical activity. [11]

Interpreting a Low Glucose With High Insulin

A patient presenting with fasting glucose of 85 mg/dL, fasting insulin of 18 µIU/mL, and HOMA-IR of 3.4 looks "fine" on a basic metabolic panel. The normal glucose is maintained only because the pancreas is working overtime. This is the compensated phase of insulin resistance, and it is precisely the window where intervention prevents progression to frank type 2 diabetes. The ADA estimates that roughly 38% of US adults are in this prediabetic range. [5]

How to Improve HOMA-IR: Evidence-Based Interventions

Lifestyle modification is the first-line intervention for elevated HOMA-IR. Drug therapy becomes appropriate when lifestyle measures fail or when the metabolic burden is high enough to warrant faster correction.

Dietary Carbohydrate Restriction

A 12-week randomized controlled trial by Westman and colleagues (N = 84) compared a very low-carbohydrate ketogenic diet (<20 g/day) to a low-glycemic-index diet in adults with type 2 diabetes. HOMA-IR fell by 2.3 units in the ketogenic group versus 0.5 units in the low-GI group (P<0.001). [12] Carbohydrate restriction reduces fasting insulin directly by lowering the postprandial glucose load that drives pancreatic secretion over the 16 to 18 waking hours.

Resistance Training

A meta-analysis in Sports Medicine (2019, 24 RCTs, N = 1,971) found that progressive resistance training 2 to 3 sessions per week for 8 to 24 weeks reduced HOMA-IR by a mean of 0.48 units (95% CI 0.29 to 0.67, P<0.001) independent of aerobic exercise or dietary change. [13] Muscle is the dominant site of insulin-mediated glucose disposal; adding 1 kg of lean mass roughly doubles the glycogen storage buffer available after each meal.

Weight Loss Magnitude and HOMA-IR

Body weight reduction of 5 to 7% consistently reduces HOMA-IR by 20 to 30% in overweight adults. The Diabetes Prevention Program (N = 3,234) showed that a structured lifestyle intervention producing 7% weight loss reduced HOMA-IR from a baseline mean of 4.6 to 3.1 at 1 year. [14] Semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N = 1,961) produced mean 14.9% weight loss at 68 weeks versus 2.4% with placebo; a sub-analysis reported mean HOMA-IR reduction of 1.5 units in the active arm. [15]

Metformin and HOMA-IR

Metformin 1,500 to 2,000 mg/day reduces hepatic glucose output and, secondarily, fasting insulin. In the Diabetes Prevention Program, the metformin arm reduced HOMA-IR from 4.6 to 3.8 at 1 year, a smaller effect than lifestyle but meaningful for patients unable to commit to intensive behavioral change. [14] Metformin is approved by the FDA for type 2 diabetes management and used off-label for prediabetes and metabolic optimization. [16]

Berberine as an Adjunct

Berberine 500 mg three times daily reduced HOMA-IR by a mean of 1.28 units (P<0.01) in a 2012 meta-analysis of 14 RCTs (N = 1,068 patients with type 2 diabetes or metabolic syndrome). [17] Effect size is smaller than metformin or structured weight loss, but berberine may be appropriate as an adjunct when patients decline prescription therapy.

HOMA-IR in Special Populations

Polycystic Ovary Syndrome (PCOS)

Insulin resistance is present in 65 to 80% of women with PCOS regardless of body weight, and HOMA-IR is a recommended screening tool per the 2023 International Evidence-Based Guideline for PCOS. [18] The ACOG Practice Bulletin on PCOS notes that hyperinsulinemia drives excess androgen production via ovarian theca-cell stimulation, making HOMA-IR reduction a therapeutic target, not just a biomarker. A target below 1.5 is reasonable in lean PCOS; below 1.0 is the aim once weight and diet are optimized.

Testosterone Replacement Therapy (TRT)

Hypogonadal men have higher HOMA-IR at baseline, and testosterone replacement therapy at physiologic doses (testosterone cypionate 100 to 200 mg/week or equivalent) reduces HOMA-IR modestly. A 2016 systematic review (11 RCTs, N = 1,083) in European Journal of Endocrinology found TRT reduced HOMA-IR by a mean of 0.46 units (P<0.05) in hypogonadal men with metabolic syndrome. [19] The effect is likely mediated by increased lean mass, reduced visceral fat, and direct hepatic insulin sensitization.

Aging and Sarcopenic Obesity

In adults over age 65, HOMA-IR often underestimates insulin resistance because diminished pancreatic beta-cell reserve blunts the fasting insulin response. A frail older adult may have a reassuringly low HOMA-IR of 1.2 with an HbA1c already at 6.1% because the beta cells are exhausted, not because insulin sensitivity is good. Combining HOMA-IR with a 2-hour postprandial glucose or a fasting C-peptide provides a more complete picture in this population. [20]

Testing Protocol: How to Get an Accurate HOMA-IR

Pre-Test Requirements

Accurate HOMA-IR requires a minimum 8-hour fast. Ideally the patient fasts 10 to 12 hours, takes no glucose-containing supplements, and avoids strenuous exercise the evening before. Biotin (vitamin B7) supplementation above 5 mg/day can falsely lower insulin on many immunoassay platforms; patients should hold biotin for 48 hours before testing. [21]

Which Labs to Order

Order simultaneously: fasting plasma glucose and fasting serum insulin. If the lab offers a metabolic panel that includes both, use it for cost efficiency. Request a lipid panel and fasting C-peptide if this is a baseline longevity assessment, as these add context HOMA-IR alone cannot provide.

Frequency of Retesting

For an adult with a normal HOMA-IR at baseline, annual retesting is sufficient. If you are actively treating elevated HOMA-IR through diet, exercise, or medication, retesting at 90 days captures the response to intervention while the habit is still forming. Fasting insulin responds to dietary change faster than HbA1c; a 4-week low-carbohydrate intervention can reduce HOMA-IR by 0.5 to 1.0 units before HbA1c shifts at all.

HOMA-IR vs. Other Insulin Resistance Markers

HOMA-IR is one of several surrogate markers for insulin resistance. Each has different strengths.

| Marker | What It Measures | Practical Advantage | Key Limitation | |---|---|---|---| | HOMA-IR | Fasting-state hepatic IR | Cheap, single blood draw | Misses postprandial IR | | Fasting Insulin alone | Beta-cell output at rest | Simpler; one value | No glucose context | | Triglyceride/HDL ratio | Atherogenic dyslipidemia associated with IR | Derived from standard lipid panel | Ethnicity-dependent accuracy | | 1-hour postprandial glucose | Early glucose dysregulation | Catches IR before fasting glucose rises | Requires OGTT; less practical | | Hyperinsulinemic-euglycemic clamp | True whole-body insulin sensitivity | Gold standard | Research only; not clinical |

A 2021 review in Frontiers in Endocrinology compared HOMA-IR, the triglyceride-glucose (TyG) index, and fasting insulin as predictors of incident type 2 diabetes in 7 prospective cohorts. HOMA-IR and TyG performed comparably (AUC ~0.74 to 0.76), while fasting insulin alone had an AUC of 0.68. [22] Using both HOMA-IR and the TyG index together offers better risk stratification than either marker alone.

Key Quotes From Guidelines and Clinicians

The ADA's 2024 Standards of Medical Care state: "Insulin resistance is a central feature of type 2 diabetes and prediabetes, and interventions that reduce insulin resistance are expected to reduce progression risk, even in individuals with normal fasting glucose." [5]

The AACE/ACE 2023 Consensus Statement on Prediabetes notes: "HOMA-IR provides a clinically accessible estimate of insulin resistance that, when combined with fasting glucose and triglycerides, improves risk stratification beyond glucose criteria alone." [23]

Putting It All Together: A Practical HOMA-IR Action Plan

A result below 1.0 means your insulin sensitivity is in the longevity-optimal range; maintain it with consistent resistance training and a diet centered on whole foods with moderate carbohydrate load. A result between 1.0 and 2.0 signals room for improvement without urgency. Cut ultra-processed carbohydrates, add two resistance-training sessions per week, and retest in 90 days.

A result of 2.0 to 3.0 warrants a structured dietary intervention (carbohydrate restriction to 50 to 100 g/day is a reasonable starting point) plus consultation with a clinician experienced in metabolic health. A result above 3.0 in a non-diabetic adult justifies a conversation about metformin, a GLP-1 receptor agonist, or a formal metabolic-medicine program, particularly if visceral adiposity, PCOS, or a family history of type 2 diabetes is also present.

Retest fasting insulin and fasting glucose together at every intervention checkpoint. A declining fasting insulin trend, even before HOMA-IR crosses a specific threshold, confirms that the pancreas is working less hard to maintain euglycemia. That trajectory, sustained over 12 to 24 months, is what longevity medicine is actually measuring.

The single most actionable first step: remove liquid fructose (sugar-sweetened beverages, fruit juice, sweetened coffee drinks) from the diet entirely. A 10-week controlled trial by Stanhope and colleagues (N = 85) showed that isocaloric replacement of glucose beverages with fructose-sweetened beverages raised fasting insulin by 20% and HOMA-IR by 0.87 units (P<0.01). [24]